Yup, that’s the biggest tell. Rather than focusing on FDA clearance for L in GBM, they are going after manufacturing preparations in the US to support new trials with in-licensed Roswell tech. And that too after 5+ years from data lock. Ignoring world’s biggest and most lucrative immunotherapy market (over 50% of the world’s revenue comes from US; UK accounts for less than 5%) is a sign that L will be sidelined. More excuses and dangling of carrots in store for bag holders. Easy money for LP’s financiers and shorts in 2026 and 2027 until they run out of shares again! ;)
LP blew the dust off Revimmune Ltd (UK), with a view to run (start from scratch, DIRECT Trial, with Ashkan as Lead Investigator, but that has died a death, after the Regulator gave them a reality check!
Market Data 
Markets 
AI
